Thyromegaly Management

Diagnostic Approach

The American College of Endocrinology recommends measuring serum TSH first as it is the single best initial test of thyroid function, with elevated TSH (>1.64 mU/L) substantially increasing malignancy risk in nodular disease 4
The American Thyroid Association suggests free T4 measurement should follow if TSH is abnormal to classify the thyroid dysfunction as primary hypothyroidism, subclinical hypothyroidism, hyperthyroidism, or subclinical hyperthyroidism 1
Serum calcitonin should be measured as an integral part of thyroid nodule evaluation to screen for medullary thyroid cancer, as it has higher sensitivity than fine-needle aspiration for this malignancy 2, 3
Neck ultrasound is essential to assess thyroid size, echotexture, presence of nodules, and cervical lymphadenopathy 2, 1, 4

Fine-needle aspiration biopsy (FNAB) is recommended for solid hypoechoic nodules ≥1 cm or with suspicious ultrasound characteristics (hypoechogenicity, microcalcifications, absence of peripheral halo, irregular borders, regional lymphadenopathy) 2, 1
FNAB should be repeated if initial samples are inadequate; false negatives occur in 5-10% of cases, so maintain clinical suspicion if other worrisome features are present 1

For hyperfunctioning (hot) nodules identified on thyroid scan, therapy options include radioactive iodine (I-131) ablation or surgical removal 1
Total or near-total thyroidectomy is the initial treatment for differentiated thyroid carcinoma ≥1 cm, or regardless of size if metastatic, multifocal, or familial 2, 3
Radioiodine ablation (131-I) is recommended post-operatively in high-risk and low-risk patients to ablate remnant thyroid tissue and potential microscopic residual tumor, but not in very low-risk patients 2, 3

At 2-3 months post-treatment, check thyroid function tests (FT3, FT4, TSH) to verify adequate levothyroxine suppressive therapy 6
Low-risk patients with undetectable stimulated Tg (<1.0 ng/ml) and normal neck ultrasound are considered in complete remission with recurrence risk <1% at 10 years and may shift from suppressive to replacement levothyroxine therapy (TSH within normal range) 6

Never rely on Tg measurements in the presence of Tg antibodies, as they invalidate the results 6
Do not omit neck ultrasound evaluation, as it detects structural disease that may not correlate with Tg levels and can identify suspicious lymphadenopathy 6, 4
Avoid routine suppressive levothyroxine therapy for benign nodules, as it may cause or worsen osteoporosis, especially in postmenopausal women 1
Maintain clinical suspicion despite negative FNAB: false negatives occur in 5-10% of cases, so consider surgery if other worrisome clinical or ultrasound features persist 1